Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy

W. R. C. Knight1,2, J. Zylstra1, M. Van Hemelrijck3, N. Griffin4, A. E. T. Jacques4, N. Maisey5, C. R. Baker1, J. A. Gossage1,2,6, J. Lagergren1,2,6 and A. R. Davies1,2,6

1Department of Surgery, Guy’s and St Thomas’ Oesophago-Gastric Centre, 2Division of Cancer Studies and 3Translational Oncology and Urology Research (TOUR), Division of Cancer Studies King’s College London, and Departments of 4Radiology and 5Oncology, Guy’s and St Thomas’ Hospital, London, UK, and 6Gastrointestinal Research Unit, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden, on behalf of the Guy’s and St Thomas’ Oesophago-Gastric Research Group

Correspondence to: Mr W. R. C. Knight, Department of General Surgery, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, UK (e-mail: william.r.knight@gmail.com)

Background: Tumour recurrence following oesophagectomy for oesophageal cancer is common despite neoadjuvant treatment. Understanding patterns of recurrence and risk factors associated with loco-regional and systemic recurrence might influence future treatment strategies.

Methods: This was a cohort study involving patients undergoing resection for adenocarcinoma or squamous cell carcinoma of the oesophagus between 2000 and 2014. Clinicopathological factors associated with locoregional and systemic recurrence were analysed using multivariable logistic regression to determine odds ratios (ORs) and 95 per cent confidence intervals.

Results: Some 698 patients were identified. Lymphovascular invasion (OR 2.09, 95 per cent c.i. 1.18 to 3.71) and preoperative stenting (OR 3.70, 1.34 to 10.23) were independent risk factors for isolated locoregional recurrence. Pathological nodal disease in patients with pT1–2 (pN1: OR 2.72, 1.35 to 5.48; pN2–3: OR 5.00, 2.35 to 10.66) or pT3–4 (pN1: OR 3.03, 1.51 to 6.07; pN2–3: OR 5.75, 3.15 to 10.49) disease predisposed to systemic recurrence. Poor or no response to chemotherapy was also an independent risk factor for isolated systemic recurrence (OR 1.85, 1.05 to 3.26). A positive resection margin (R1 resection) was not associated with a significantly increased risk of isolated locoregional recurrence (OR 1.37, 0.81 to 2.33).

Conclusion: These findings confirm that oesophageal adenocarcinoma is frequently a systemic disease. Understanding the key predictors of local and systemic recurrence may facilitate the tailoring of oncological therapies to the individual patient.

Funding information
GSTT cancer charity
Guy’s and St Thomas’ (GSTT) Charity

Paper accepted 30 October 2017
Published online 12 January 2018 in Wiley Online Library (www.bjsopen.com). DOI: 10.1002/bjs5.30

Introduction

Oesophageal cancer is the sixth most common cancer worldwide and is responsible for 400,000 deaths a year1. Once the disease has progressed beyond the mucosa, oesophagectomy is generally an important element in any treatment protocol designed to achieve cure. Unfortunately, a high proportion of patients have evidence of micrometastasis at the time of surgery, and half of all resected patients develop recurrent disease within 2 years of surgery2–6. Systemic recurrence remains the most common cause of death following oesophageal resection and, as a result, most patients are offered oncological therapies in combination with surgery, in the hope of reducing this risk7. Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) have both been shown to improve survival compared with surgery alone7–9. Although both may have a local downstaging effect on the primary tumour, this is widely acknowledged to be more pronounced following NACRT8. Debate still exists regarding whether this local benefit of NACRT is at the cost of reduced systemic efficacy compared with NAC9.

© 2018 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Understanding patterns of recurrence of oesophageal cancer after surgery may be useful in stratifying patients to oncological treatment alternatives and informing future trials. This study was designed to identify clinicopathological factors associated with locoregional and systemic recurrence in oesophageal adenocarcinoma.

Methods
This was a cohort study based on a prospectively developed database of consecutive resections performed at Guy’s and St Thomas’ Oesophago-Gastric Centre, London, UK. The study involved all patients who underwent oesophagectomy between 2000 and 2014 for adenocarcinoma or squamous cell carcinoma (SCC). Patients with Siewert type III junctional tumours having NACRT and those undergoing oesophagogastrectomy for benign or rare malignant pathologies (melanoma, sarcoma and neuroendocrine tumours) were excluded. The main outcome measure was the presence of tumour recurrence. Other outcome measures were time to recurrence and survival. Follow-up ended in February 2016.

Clinical management
Patients underwent a standard protocol of investigations including oesophagogastroduodenoscopy, CT, endoscopic ultrasonography and, from 2007, fluorodeoxyglucose-PET. The practice of NAC evolved during the study period and followed standard indications and regimens, as supported by RCT evidence. Surgical resection included transthoracic (TTO) or transhiatal (THO) oesophagectomy, determined by tumour characteristics and individual surgeon preference. Histological staging was standardized to meet the seventh edition of TNM criteria. Pathological specimens were processed and reported using the Royal College of Pathologists’ guidelines. A positive circumferential resection margin (CRM) was defined as tumour within 1 mm of the cut margin. Adjuvant therapy was determined by the multidisciplinary team (MDT), based on the positivity of resection margins, pathological nodal status and the postoperative performance status of the patient.

Tumour recurrence criteria
Tumour recurrences were classified as either locoregional or systemic, and were diagnosed radiologically or histologically with MDT consensus. Locoregional recurrence was further subcategorized into regional lymph node, mediastinal mass, abdominal mass or anastomotic recurrence. Regional lymph nodes included mediastinal, left gastric and coeliac nodes for patients with gastro-oesophageal junction tumours, defined on the basis that they were within the lymphatic distribution of the primary tumour and fell inside a therapeutic radiotherapy field. Mediastinal and abdominal recurrences represented mass recurrences in the original tumour bed, acknowledging some inevitable overlap with the local lymph node group. Anastomotic recurrences were defined as intraluminal disease on endoscopy, confirmed histologically.

Systemic recurrence was divided into haematogenous, distant lymph node and peritoneal recurrences. Haematogenous recurrences included lung, liver, bone, adrenal and brain. Distant nodal metastases included supraclavicular, para-aortic, portal and mesenteric nodes considered to be outside a conventional radiotherapy or surgical field. Peritoneal disease was examined independently as it was considered to represent a separate (transcoelomic) mode of dissemination.

In all, six outcome groups were examined: no recurrence, any recurrence, locoregional recurrence, systemic recurrence, isolated locoregional recurrence and isolated systemic recurrence. The locoregional group included patients who experienced isolated locoregional recurrence plus those who had locoregional recurrence as part of a mixed pattern. This distinction was made to analyse the risk of developing any local recurrence. The same applied to the systemic recurrence group. Whether local recurrence occurred in isolation or as part of a systemic recurrence, it still represented a failure of local control. Isolated recurrence was defined as a situation with no evidence of metachronous recurrence within 6 weeks. If a second recurrence was confirmed within 6 weeks of the first, it was deemed synchronous.

Statistical analysis
To evaluate which patient and tumour characteristics were predictive of each recurrence type, crude logistic regression analysis was performed first. Multivariable logistic regression with backward stepwise elimination (α = 0.20) was then used to identify individual predictors of recurrence. Only the adenocarcinoma subgroup had sufficient numbers to be included in the statistical models. Patient and tumour characteristics examined were: sex (male or female), age (continuous), preoperative stenting (yes or no), NAC (yes or no), surgery type (TTO versus THO), resection outcome (R0 or R1), lymphovascular invasion (yes or no), pathological stage (pT0 N0, pT1–2 N0, pT1–2 N1, pT1–2 N2–3, pT3–4 N0, pT3–4 N1, pT3–4 N2–3), pathological grade (poorly differentiated, moderately differentiated,
### Table 1  Demographics and clinical characteristics of participating patients with oesophageal cancer according to histological type

|                          | Adenocarcinoma (n = 578) | Squamous cell carcinoma (n = 120) |
|--------------------------|---------------------------|-----------------------------------|
| Mean age (years)         | 62.5                      | 62.4                               |
| Sex ratio (M:F)          | 494:84                    | 56:64                              |
| Neoadjuvant treatment    |                           |                                   |
| None                     | 153 (26.5)                | 57 (47.5)                          |
| Chemotherapy             | 424 (73.4)                | 63 (52.5)                          |
| Missing                  | 1 (0.2)                   |                                   |
| Surgery                  |                           |                                   |
| Transthoracic            | 281 (48.6)                | 72 (60.0)                          |
| Transhiatal              | 297 (51.4)                | 48 (40.0)                          |
| Pathological stage       |                           |                                   |
| T0 N0                    | 22 (3.8)                  | 11 (9.2)                           |
| T1–2 N0                  | 123 (21.3)                | 12 (10.0)                          |
| T1–2 N1                  | 66 (11.4)                 | 38 (31.7)                          |
| T1–2 N2–3                | 49 (8.5)                  | 8 (6.7)                            |
| T3–4 N0                  | 74 (12.8)                 | 2 (1.7)                            |
| T3–4 N1                  | 70 (12.1)                 | 25 (20.8)                          |
| T3–4 N2–3                | 161 (27.9)                | 16 (13.3)                          |
| Missing                  | 13 (2.2)                  | 8 (6.7)                            |
| Pathological grade       |                           |                                   |
| Poorly differentiated    | 220 (38.1)                | 31 (25.8)                          |
| Moderately differentiated | 311 (53.8)                | 66 (55.0)                          |
| Well differentiated      | 13 (2.2)                  | 8 (6.7)                            |
| Complete pathological response | 22 (3.8)          | 11 (9.2)                           |
| Missing                  | 12 (2.1)                  | 4 (3.3)                            |
| Response to chemotherapy |                           |                                   |
| Mandard 1 (complete pathological response) | 22 (3.8) | 11 (9.2) |
| Mandard 2 (good response) | 18 (3.1)                 | 3 (2.5)                            |
| Mandard 3 (moderate response) | 126 (21.8)           | 15 (12.5)                          |
| Mandard 4 (poor response) | 194 (33.6)                | 27 (22.5)                          |
| Mandard 5 (no response)  | 39 (6.7)                  | 4 (3.3)                            |
| n.a.                     | 153 (26.5)                | 57 (47.5)                          |
| Missing                  | 26 (4.5)                  | 3 (2.5)                            |
| Resection margin         |                           |                                   |
| R0                       | 303 (52.4)                | 77 (64.2)                          |
| R1                       | 275 (47.6)                | 43 (35.8)                          |
| CRM within 1 mm of margin (UK) | 272 (47.1)          | 43 (35.8)                          |
| CRM tumour at margin (USA) | 104 (18.0)            | 13 (10.8)                          |
| Longitudinal margin positive | 42 (7.3)             | 1 (0.8)                            |
| Lymphovascular invasion  |                           |                                   |
| Yes                      | 309 (53.5)                | 42 (35.0)                          |
| No                       | 266 (46.0)                | 78 (65.0)                          |
| Missing                  | 3 (0.5)                   | 0 (0)                              |
| Two-field positive lymph nodes | 140 (24.2)         | 13 (10.8)                          |
| Yes                      | 438 (75.8)                | 107 (89.2)                         |
| No                       |                           |                                   |
| Adjuvant treatment       |                           |                                   |
| None                     | 254 (43.9)                | 69 (57.5)                          |
| Chemotherapy             | 202 (34.9)                | 29 (24.2)                          |
| Chemoradiotherapy        | 99 (17.1)                 | 18 (15.0)                          |
| Missing                  | 23 (4.0)                  | 4 (3.3)                            |

Values in parentheses are percentages. n.a., not applicable; CRM, circumferential resection margin.

well differentiated or complete pathological response), Mandard tumour regression score (1, 2–3, 4–5, or not applicable) and adjuvant treatment (none, chemotherapy or chemoradiotherapy). Time to recurrence was considered to be less relevant, particularly as most recurrences after oesophagectomy occur within 2 years⁴⁻⁶. It was therefore decided to treat the outcome ‘recurrence’ as a categorical variable using logistic regression. To verify this assumption, an additional Cox regression analysis using time to recurrence as the primary outcome was performed.
Patterns of recurrence in oesophageal cancer after oesophagectomy

Table 2  Distribution of local and systemic recurrence following surgery for oesophageal cancer according to histology and neoadjuvant chemotherapy groups

| Recurrence       | Adenocarcinoma* | Squamous cell carcinoma |
|------------------|-----------------|-------------------------|
|                  | All (n = 578)   | NAC (n = 424)           | No NAC (n = 153)   | All (n = 120) | NAC (n = 63) | No NAC (n = 57) |
| No               | 297 (51.4)      | 202 (47.6)              | 93 (60.8)          | 75 (62.5)     | 40 (63)      | 35 (61)        |
| Yes              | 281 (48.6)      | 222 (52.4)              | 60 (39.2)          | 45 (37.5)     | 23 (37)      | 22 (39)        |
| Local recurrence |                 |                         |                     |               |              |                |
| Isolated         | 156 (27.0)      | 121 (28.5)              | 35 (22.9)          | 27 (22.5)     | 16 (25)      | 11 (19)        |
| Anastomotic      | 62 (10.7)       | 47 (11.1)               | 15 (9.8)           | 14 (11.7)     | 9 (14)       | 5 (9)          |
| Lymph node       | 34 (5.9)        | 23 (5.4)                | 11 (7.2)           | 14 (11.7)     | 8 (13)       | 6 (11)         |
| Mediastinal nodal| 85 (14.7)       | 67 (15.8)               | 18 (11.8)          | 8 (6.7)       | 6 (10)       | 2 (4)          |
| Gastric nodal    | 61 (10.6)       | 48 (11.3)               | 13 (8.8)           | 6 (5.0)       | 4 (6)        | 2 (4)          |
| Coeliac nodal    | 7 (1.2)         | 6 (1.4)                 | 1 (0.7)            | 0 (0)         | 0 (0)        | 0 (0)          |
| Abdominal        | 3 (0.5)         | 3 (0.7)                 | 0 (0)              | 2 (1.7)       | 2 (3)        | 0 (0)          |
| Mediastinal      | 35 (6.1)        | 26 (6.1)                | 9 (5.9)            | 7 (5.8)       | 4 (6)        | 3 (5)          |
| Systemic recurrence | 218 (37.7) | 174 (41.0) | 44 (28.8) | 31 (25.8) | 17 (27) | 17 (30) |
| Isolated         | 124 (21.5)      | 47 (11.1)               | 23 (15.0)          | 18 (15.0)     | 7 (11)       | 11 (19)        |
| Haematogenous    | 118 (20.4)      | 96 (22.6)               | 22 (14.4)          | 15 (12.5)     | 8 (13)       | 7 (12)         |
| Lung             | 68 (11.8)       | 52 (12.3)               | 16 (10.5)          | 13 (10.8)     | 6 (10)       | 7 (12)         |
| Liver            | 67 (11.6)       | 52 (12.3)               | 15 (9.8)           | 14 (11.7)     | 7 (11)       | 7 (12)         |
| Bone             | 38 (6.6)        | 31 (7.3)                | 7 (4.6)            | 3 (2.5)       | 2 (3)        | 1 (2)          |
| Brain            | 14 (2.4)        | 13 (3.1)                | 1 (0.7)            | 0 (0)         | 0 (0)        | 0 (0)          |
| Nodal            | 39 (6.7)        | 31 (7.3)                | 8 (5.2)            | 8 (6.7)       | 4 (6)        | 4 (7)          |
| Supraclavicular  | 10 (1.7)        | 6 (1.4)                 | 4 (2.6)            | 4 (3.3)       | 1 (2)        | 3 (5)          |
| Para-aortic      | 13 (2.2)        | 12 (2.8)                | 1 (0.7)            | 3 (2.5)       | 3 (5)        | 0 (0)          |
| Mesenteric       | 5 (0.9)         | 5 (1.2)                 | 0 (0)              | 0 (0)         | 0 (0)        | 0 (0)          |
| Porta hepatitis  | 5 (0.9)         | 3 (0.7)                 | 2 (1.3)            | 1 (0.8)       | 0 (0)        | 1 (2)          |
| Other            | 3 (0.5)         | 2 (0.5)                 | 1 (0.7)            | 0 (0)         | 0 (0)        | 0 (0)          |
| Peritoneal       | 54 (9.3)        | 43 (10.1)               | 11 (7.2)           | 5 (4.2)       | 5 (8)        | 0 (0)          |

Values in parentheses are percentages. *As shown in Table 1, information on neoadjuvant chemotherapy (NAC) was missing for one patient.

Results

Of 761 consecutive patients who underwent oesophagectomy between 2000 and 2014, 698 with adenocarcinoma (578, 82.8 per cent) or SCC (120, 17.2 per cent) were identified. Their clinicopathological features are shown in Table 1.

The mean age of patients was 62.5 years. The male to female ratio was higher for adenocarcinoma (494:84) than for SCC (64:56). In the adenocarcinoma group, 73.4 per cent of patients underwent NAC, a proportion that increased during the study interval as thresholds for NAC lowered. Of the 153 who proceeded straight to surgery, 98 (64.1 per cent) had T1–2 disease and 107 (69.9 per cent) had no nodal disease on preoperative staging.

Twenty-five patients, all with T3 disease, had stenting before surgery; all but one received NAC. Fourteen of these 25 patients had an R1 resection and eight were downstaged by NAC (5 to pT2; 3 to pT1).

Oncological outcomes

Overall recurrence-free survival of the cohort was 75.4, 53.1 and 45.2 per cent at 1, 3 and 5 years respectively. R1 resection rates were higher in the adenocarcinoma cohort (47.6 per cent) than in patients with SCC (35.8 per cent). CRM rates overall were 45.1 per cent. Longitudinal margin involvement in isolation was rare (2.2 per cent). Median follow-up was 1.62 (range 0.01 to 13.84) years.

Recurrence patterns

Of the 698 patients, 326 (46.7 per cent) developed recurrence. Patterns of recurrence according to histological subtype are shown in Table 2. There was a higher rate of overall recurrence for adenocarcinoma compared with SCC (48.6 versus 37.5 per cent respectively), despite a higher rate of NAC in the adenocarcinoma group (73.4 versus 52.5 per cent) (Table 1). This was due mainly to a higher rate of systemic recurrence in the adenocarcinoma group (37.7 versus 22.8 per cent; P = 0.013). In all, 27.0 per cent of patients with adenocarcinoma developed local recurrence, compared with 22.5 per cent of patients with SCC. However, many of these (16.3 per cent for adenocarcinoma and 10.8 per cent for SCC) were associated with synchronous systemic metastases. Rates of isolated locoregional recurrence were 10.7 and 11.7 per cent respectively.

© 2018 The Authors.
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd

www.bjsopen.com  BJS Open 2018; 1: 182–190
**Table 3** Crude odds ratios for risk of recurrence in patients with oesophageal adenocarcinoma

|                          | Odds ratio          |
|--------------------------|---------------------|
|                          | Any recurrence | Locoregional recurrence | Systemic recurrence | Isolated locoregional recurrence | Isolated systemic recurrence |
| Age at operation         | 0.98 (0.96, 1.00) | 0.99 (0.97, 1.01) | 0.98 (0.96, 1.00) | 1.00 (0.97, 1.03) | 0.99 (0.97, 1.01) |
| Sex                      | M                   | F                   |
|                          | 1.39 (0.87, 2.22) | 1.00 (reference) | 1.04 (0.64, 1.68) | 2.66 (0.94, 7.53) | 1.09 (0.61, 1.93) |
| Initial stage            | T1–2 N0             | T1–2 N+             |
|                          | 1.00 (reference)   | 3.05 (1.48, 6.26)  | 3.02 (1.39, 6.55) | 1.29 (0.37, 4.49) | 1.83 (0.72, 4.66) |
|                          | T3–4 N0             | T3–4 N+             |
|                          | 3.79 (2.22, 6.49)  | 3.66 (2.02, 6.65)  | 1.71 (0.70, 4.18) | 2.46 (1.22, 4.97) |
|                          | 3.30 (1.69, 6.45)  | 2.78 (1.34, 5.76)  | 2.26 (0.79, 6.45) | 2.20 (0.94, 5.16) |
| Tumour location          | Lower oesophagus    | Siewert type I      |
|                          | 1.00 (reference)   | 2.36 (1.14, 4.89)  | 2.45 (1.08, 5.56) | 1.19 (0.39, 3.57) | 1.17 (0.49, 2.81) |
|                          | THO                 | Siewert type II     |
|                          | 1.00 (reference)   | 2.00 (0.97, 4.13)  | 2.35 (1.04, 5.31) | 0.90 (0.30, 2.72) | 1.27 (0.53, 3.02) |
| Preoperative stenting    | Yes                 | No                  |
|                          | 6.88 (1.99, 23.76) | 1.00 (reference)   | 0.90 (0.30, 2.72) | 1.27 (0.53, 3.02) | 2.08 (0.81, 5.35) |
| Neoadjuvant chemotherapy | Yes                 | No                  |
|                          | 1.73 (1.19, 2.53)  | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Type of surgery          | TTO                 |
|                          | 1.49 (1.07, 2.07)  | 1.23 (0.88, 1.72)  | 1.65 (0.97, 2.82) | 1.21 (0.82, 1.81) |
|                          | THO                 |
|                          | 1.00 (reference)   | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Type of resection        | R0                  |
|                          | 2.68 (1.91, 3.75)  | 2.53 (1.79, 3.57)  | 1.37 (0.81, 2.33) | 2.01 (1.34, 3.02) |
| Lymphovascular invasion | No                  |
|                          | 3.26 (2.32, 4.60)  | 2.35 (1.59, 3.46)  | 2.66 (1.87, 3.79) | 2.10 (1.19, 3.70) | 2.11 (1.39, 3.21) |
| Pathological staging     | pT0 N0              | pT1–2 N0            |
|                          | 0.10 (0.01, 0.78)  | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                          | pT1–2 N1            |
|                          | 3.35 (1.78, 6.30)  | 2.36 (1.14, 4.90)  | 2.68 (1.38, 5.22) | 2.29 (0.79, 6.61) | 2.71 (1.21, 6.05) |
|                          | pT1–2 N2–3          |
|                          | 4.30 (2.14, 8.67)  | 1.89 (0.83, 4.30)  | 4.30 (2.10, 8.79) | 1.47 (0.41, 5.28) | 4.50 (1.98, 10.23) |
|                          | pT3–4 N0            |
|                          | 1.26 (0.66, 2.39)  | 1.24 (0.57, 2.71)  | 0.96 (0.46, 2.00) | 2.01 (0.70, 5.79) | 1.17 (0.48, 2.89) |
|                          | pT3–4 N1            |
|                          | 5.02 (2.67, 9.46)  | 4.38 (2.20, 8.71)  | 3.47 (1.82, 6.64) | 3.43 (1.28, 9.17) | 2.12 (0.93, 4.81) |
|                          | pT3–4 N2–3          |
|                          | 8.41 (4.91, 14.40) | 3.85 (2.13, 6.95)  | 6.09 (3.53, 10.25) | 2.76 (1.14, 6.67) | 4.27 (2.20, 8.27) |
| Pathological grade       | Poorly differentiated |
|                          | 1.00 (reference)   | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                          | Moderately differentiated |
|                          | 0.82 (0.58, 1.16)  | 0.81 (0.55, 1.18)  | 0.90 (0.63, 1.28) | 0.76 (0.44, 1.29) | 0.99 (0.65, 1.49) |
|                          | Well differentiated |
|                          | 0.71 (0.23, 2.19)  | 0.66 (0.18, 2.46)  | 0.89 (0.28, 2.80) | 0.55 (0.07, 4.38) | 1.02 (0.27, 3.85) |
|                          | Complete pathological response |
|                          | –                   | –                   | –                   | –                   | –                   |
|                          | Two-field positive lymph nodes |
|                          | Yes                 |
|                          | 1.70 (1.16, 2.50)  | 1.11 (0.73, 1.70)  | 1.61 (1.10, 2.37) | 1.21 (0.67, 2.19) | 1.86 (1.21, 2.87) |
|                          | No                  |
|                          | 1.00 (reference)   | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Mandart score            | 2–3                 |
|                          | 1.00 (reference)   | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                          | 4–5                 |
|                          | 2.16 (1.42, 3.30)  | 1.25 (0.79, 1.98)  | 2.07 (1.34, 3.20) | 1.14 (0.59, 2.18) | 2.33 (1.37, 3.98) |
|                          | n.a.                |
|                          | 1.05 (0.67, 1.63)  | 0.86 (0.52, 1.43)  | 1.13 (0.71, 1.81) | 0.85 (0.41, 1.75) | 1.27 (0.74, 2.30) |
| Adjuvant treatment       | None                |
|                          | 1.00 (reference)   | 1.00 (reference)   | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
|                          | Chemotherapy        |
|                          | 1.79 (1.24, 2.61)  | 2.19 (1.45, 3.33)  | 1.49 (1.02, 2.19) | 1.63 (0.90, 2.95) | 0.89 (0.56, 1.43) |

Values in parentheses are 95 per cent confidence intervals. TTO, transthoracic oesophagectomy; THO, transhiatal oesophagectomy; n.a., not applicable.
Patterns of recurrence in oesophageal cancer after oesophagectomy

Table 4  Multivariable odds ratios for risk of recurrence in the patients with oesophageal adenocarcinoma

|                        | Any recurrence | Locoregional recurrence | Systemic recurrence | Isolated locoregional recurrence | Isolated systemic recurrence |
|------------------------|----------------|-------------------------|---------------------|---------------------------------|-----------------------------|
| Sex                    |                |                         |                     |                                 |                             |
| M                      | 1.49 (0.87, 2.57) | 1.00 (0.10, 0.30)       | 2.77 (0.97, 7.96)   |                                 |                             |
| F                      | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| Preoperative tumour grade |                |                         |                     |                                 |                             |
| Poorly differentiated   | 5.48 (1.43, 21.08) | 2.88 (1.10, 7.51)       | 4.90 (0.56, 4.02)   | 1.49 (1.34, 10.23)               |                             |
| Moderately differentiated | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| Well differentiated     | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| Preoperative stenting   |                |                         |                     |                                 |                             |
| Yes                    | 1.58 (1.00, 2.50)   | 1.90 (1.17, 3.08)       | 3.08 (1.24, 7.67)   |                                 |                             |
| No                     | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| Neoadjuvant chemotherapy|                |                         |                     |                                 |                             |
| Yes                    | 1.54 (1.02, 2.35)   | –                       | 2.09 (1.18, 3.71)   |                                 |                             |
| No                     | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| Pathological staging    |                |                         |                     |                                 |                             |
| pT0 N0                 | 0.13 (0.02, 1.03)   | –                       | 0.14 (0.02, 1.13)   | 0.00 (0.15, 1.16)               | 1.31 (0.15, 11.64)          |
| pT1–2 N0               | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| pT1–2 N1               | 2.98 (1.51, 5.86)   | 2.08 (0.98, 4.42)       | 2.72 (1.35, 5.48)   | 5.00 (2.35, 10.66)              | 4.17 (1.81, 9.58)           |
| pT1–2 N2–3             | 4.10 (1.93, 8.71)   | 1.72 (0.74, 4.03)       | 5.00 (2.35, 10.66)  | 4.17 (1.81, 9.58)              | 3.12 (1.56, 6.24)           |
| pT3–4 N0               | 1.09 (0.54, 2.18)   | 1.18 (0.53, 2.63)       | 0.79 (0.37, 1.72)   | 0.98 (0.39, 2.47)              | 1.75 (0.76, 4.05)           |
| pT3–4 N1               | 3.80 (1.89, 7.65)   | 4.01 (1.95, 8.26)       | 3.03 (1.51, 6.07)   | 3.03 (1.51, 6.07)              | 3.12 (1.56, 6.24)           |
| pT3–4 N2–3             | 6.26 (3.34, 11.72)  | 3.78 (2.02, 7.08)       | 5.73 (3.15, 10.49)  | 5.73 (3.15, 10.49)             | 3.12 (1.56, 6.24)           |
| Mandard score 1         |                |                         |                     |                                 |                             |
| 2–3                    | 1.00 (reference)    | 1.00 (reference)         | 1.00 (reference)   |                                 |                             |
| 4–5                    | 1.85 (1.05, 3.26)   | –                       | 2.97 (1.18, 7.43)   |                                 |                             |
| n.a.                   | 2.97 (1.18, 7.43)   | –                       | 2.97 (1.18, 7.43)   |                                 |                             |

The model was based on backward elimination with $\alpha = 0.20$ and exclusion of initial stage, two-field positive nodes and tumour location. Values in parentheses are 95 per cent confidence intervals. n.a., not applicable.

There was a higher rate of haematogenous metastasis in patients with adenocarcinoma than in those with SCC (20.4 versus 12.5 per cent respectively). Although 30.5 per cent (64 of 210) of patients with pN2–3 adenocarcinoma developed haematogenous recurrence, this also occurred in 11.9 per cent (26 of 219) of patients with pN0 and 23.5 per cent (32 of 136) of those with pN1 disease. Of the 318 patients with an R1 resection, 194 (61.0 per cent) suffered recurrent disease, which was isolated locoregional recurrence in only 42 patients (13.2 per cent). Most of the patients with recurrence after R1 resection (150 of 194, 77.3 per cent) developed systemic recurrence. There appeared to be no correlation between Siewert type I and II junctional tumours regarding rates of peritoneal recurrence: 26 of 261 (10.0 per cent) and 30 of 290 (10.3 per cent) respectively. Most patients (21 of 33, 64 per cent) who had coeliac lymph node recurrence were found to have synchronous systemic disease. Thirty-three patients had a complete pathological response to NAC. There were no recorded recurrences among these patients. Systemic recurrence rates in patients with adenocarcinoma who had undergone NAC were 18.9 per cent (28 of 148) for pN0, 44.5 per cent (49 of 110) for pN1, 57 per cent (51 of 89) for pN2 and 60 per cent (46 of 77) for pN3 disease.

Factors associated with systemic and locoregional recurrence in adenocarcinoma

Crude and multivariable analysis of recurrence patterns was performed only in patients with adenocarcinoma (Tables 3 and 4). In crude analysis, there was an association between nodal status and the risk of all types of recurrence,
particularly pT3–4 N2–3 disease (any recurrence: OR 8.41, 95 per cent c.i. 4.91 to 14.40; locoregional recurrence: OR 3.85, 2.13 to 6.95; systemic recurrence: OR 6.09, 3.53 to 10.52; isolated locoregional recurrence: OR 2.76, 1.14 to 6.67; isolated systemic recurrence: OR 4.27, 2.20 to 8.27). Lymphovascular invasion was associated with all forms of recurrence, and stenting was associated with locoregional recurrence (OR 3.06, 1.25 to 7.53) and isolated locoregional recurrence (OR 3.83, 1.41 to 10.38). Mandard score 4–5 (poor or no response) was associated with an increased risk of systemic (OR 2.07, 1.34 to 3.20) and isolated systemic (OR 2.33, 1.37 to 3.98) recurrence.

In multivariable analysis, lymphovascular invasion (OR 2.09, 95 per cent c.i. 1.18 to 3.71) and preoperative stenting (OR 3.70, 1.34 to 10.23) were independent risk factors for isolated locoregional recurrence. Advanced pathological stage with pT3–4 N1 (OR 4.01, 1.95 to 8.26) and pT3–4 N2–3 (OR 3.78, 2.02 to 7.06) disease was a risk factor for locoregional recurrence.

Poor or no response to chemotherapy (Mandard score 4–5: OR 1.85, 95 per cent c.i. 1.05 to 3.26) was an independent risk factor for isolated systemic recurrence. Pathological nodal status was also an independent risk factor for systemic recurrence, in patients with both pT1–2 (pN1: OR 2.72, 1.35 to 5.48; pN2–3: OR 5.00, 2.35 to 10.66) and T3–4 (pN1: OR 3.03, 1.51 to 6.07; pN2–3: OR 5.75, 3.15 to 10.49) disease.

In univariable analysis, R1 resection was associated with higher rates of overall (OR 2.68, 95 per cent c.i. 1.91 to 3.75), locoregional (OR 1.86, 1.28 to 2.70) and systemic (OR 2.53, 1.79 to 3.57) recurrence, but not isolated locoregional recurrence (OR 1.37, 0.81 to 2.33). An R1 resection did not increase risk of any recurrence type on multivariable analysis.

**Discussion**

This study has indicated that lymphovascular invasion and preoperative stenting are independently associated with isolated locoregional recurrence after oesophagectomy for adenocarcinoma, whereas advanced nodal disease and a poor response to chemotherapy predict systemic recurrence. Patients with adenocarcinoma had a higher rate of systemic recurrence than those with SCC. A positive resection margin did not lead to significantly higher rates of local recurrence, and the majority of these patients died from systemic disease. In contrast to other series, this study did not show a higher rate of local recurrence in the SCC group.

Some methodological issues deserve attention. Although many previous studies have examined recurrence patterns following oesophagectomy alone, few have assessed this question in an era when NAC has been used routinely. Given the current debate on the optimal perioperative treatment of oesophageal adenocarcinoma, the pattern of disease recurrence is an important issue. This was a relatively large study in terms of patient numbers, from a single centre with mature follow-up data. Analysis of adenocarcinoma and SCC separately reduced the heterogeneity of the results. Although patient numbers allowed adjustment for several confounding factors, the retrospective nature of the study and the evolution of perioperative treatment strategies over the study period were sources of potential bias. Some confounders such as advanced T status, stenting and positive resection margins had strong interactions.

There is little consensus as to how locoregional and systemic recurrences should be categorized. Intuitively, locoregional recurrences would best be defined as those occurring within an agreed target area of a given locoregional therapy, either a field of surgical resection with lymphadenectomy or radiotherapy. Previous studies have used both criteria but with areas of notable contention such as the inclusion of supraclavicular lymph nodes as locoregional recurrence for SCC. Equally contentious in the context of adenocarcinoma is the status of coeliac lymph nodes, which were traditionally considered M1a disease in the sixth TNM classification. These nodes are variably included by surgeons and oncologists in lymphadenectomy and radiotherapy fields. Interestingly, the present data showed high rates of coexisting systemic recurrence in patients with coeliac lymph node recurrence, as found elsewhere. This implies that locoregional control is not the predominant issue in patients with involved coeliac nodes. It is also important to recognize that mode of spread may vary between patients, and although haematogenous, distant lymph node and peritoneal recurrences were all classified as distant metastases, the risk factors for each of these modes of distribution may be different. An understanding of this may guide future oncological therapeutic strategies.

Pathological nodal status is a known marker of recurrence and prognosis. One multicentre study analysed 1053 patients, and demonstrated that the risk of systemic recurrence increased with pathological nodal status in patients progressing straight to surgery without NAC (pN0, 16 per cent; pN1, 44 per cent; pN2, 69 per cent; pN3, 93 per cent; \( P < 0.001 \)). The present study found similar systemic recurrence rates in patients with pN0, pN1 and pN2 adenocarcinoma who had undergone NAC; however, the systemic recurrence rate in patients with pN3 disease was 60 per cent. Although NAC might reduce the systemic recurrence rate in patients with more advanced nodal disease, there...
is little evidence to support a major effect in patients who seem to have a more favourable disease stage.

The finding that patients with a poor response to NAC have double the risk of systemic recurrence compared with those with a good or moderate response is inherently logical. In keeping with this, a recent study found no survival benefit for adjuvant platinum-based chemotherapy in patients who were non-responders in the neoadjuvant setting. Prospective trials are required to determine any benefit of changing or tailoring chemotherapy regimens in non-responding patients.

The present study confirmed that the incidence of isolated locoregional recurrence within a surgical or radiation field is rare. Even in patients who might be considered at high risk for isolated locoregional recurrence, such as those with a positive resection margin, recurrence occurs in a predominantly systemic fashion. A previous study documented the same finding after NACRT, with isolated locoregional recurrence being found in only 9 and 3 per cent respectively of patients receiving surgery alone and those who had NACRT. Most patients developed systemic recurrence following NACRT. In that same study, lymph node-positive patients and those who did not receive neoadjuvant treatment had an increased risk of local recurrence, but the benefit of treatment was greatest in the SCC group. Given that the outcomes of most patients with adenocarcinoma will be dictated by the presence of systemic disease, the role for radiotherapy as standard practice in all patients should still be questioned, particularly as this is often accompanied by a reduction in systemic chemotherapy dose. This is indirectly supported by follow-up data of complete responders to NACRT, who continue to suffer significant rates of systemic relapse despite having no residual tumour at the time of resection. In contrast, none of the patients who showed a complete pathological response following NAC in the present series had a recurrence.

Preoperative stenting remains a contentious issue. In the present series, one-third of stented patients were downstaged following NAC. Despite this, stenting remained a significant independent risk factor for locoregional recurrence. Whether this was simply a reflection of a locally advanced tumour or whether the stenting itself predisposed to recurrence by expanding the tumour towards its lateral margins is unclear. Although stenting poses challenges for radiotherapy field planning, the higher rates of local recurrence in stented patients might suggest that this group be given particular consideration for radiotherapy before or after surgery.

Lymphovascular invasion is a known prognostic factor in both SCC and adenocarcinoma, and has been associated with a higher risk of recurrence. In the present study, lymphovascular invasion was an independent risk factor for overall recurrence and isolated locoregional recurrence. The rate of lymphovascular invasion in the adenocarcinoma group was 53.5 per cent, compared with 35.0 per cent in the SCC group, in line with other studies.

This study indicates that adenocarcinoma and SCC have differing pathophysiology. Trials that involve both histopathologies should take this into account. Understanding how clinicopathological factors influence recurrence patterns in both main histological types of oesophageal cancer may be useful in creating tailored neoadjuvant and adjuvant treatment pathways. The presence of lymphovascular invasion, stenting and T3–4 with node-positive disease predisposes to local recurrence in adenocarcinoma. Nodal status and poor response to chemotherapy predict systemic recurrence. As staging modalities become more sensitive, trials will be needed to determine whether treatment strategies based on risk of recurrence will yield improvements in long-term survival.

Acknowledgements

The authors thank GSTT cancer charity for funding the research degree of W.R.C.K.

Disclosure: The authors declare no conflict of interest.

References

1 Ferlay J1, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.
2 Meguid RA, Hooker CM, Taylor JT Kleinberg LR, Cattaneo SM, Sussman MS et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg 2009; 138: 1309–1317.
3 Ryan P, Furlong H, Murphy CG, O’Sullivan F, Walsh TN, Shanahan F et al. Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10-year follow-up confirms prognostic significance. Cancer Med 2015; 4: 1281–1288.
4 Lou F, Sima CS, Adusumilli PS, Bains MS, Sarkaria IS, Rusch VW et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol 2013; 8: 1558–1562.
5 Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616–1623.
6 Davies AR, Pillai A, Sinha P, Sandhu H, Adeniran A, Mattsson F et al. Factors associated with early recurrence.
and death after esophagectomy for cancer. *J Surg Oncol* 2014; **109**: 459–464.

7 Allum WH, Stenning SP, Bancewicz J, Clark PL, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. *J Clin Oncol* 2009; **27**: 5062–5067.

8 van Hagen P, Hulshof M, van Lanschot J, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP *et al.* Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012; **366**: 2074–2084.

9 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M *et al.* Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; **355**: 11–20.

10 Smit JK, Pultrum BB, Van Dullemen HM, Van Dam GM, Groen H, Plukker JT. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. *Am J Surg* 2010; **200**: 446–453.

11 Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. *Ann Surg* 2001; **234**: 360–367.

12 Oppedijk V, van der Gaast A, van Lanschot JJ van Hagen P, van Os R, van Rij CM *et al.* Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. *J Clin Oncol* 2014; **32**: 385–391.

13 Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Hölscher A, Law S *et al.* Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. *Ann Surg* 2008; **248**: 979–985.

14 Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Muntaz E *et al.* The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. *J Surg Oncol* 2017; **115**: 821–829.

15 Brücher BLDM, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. *Cancer* 2001; **92**: 2228–2233.

16 Von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. *J Clin Oncol* 2005; **23**: 874–879.

17 Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. *Br J Cancer* 2015; **113**: 1427–1433.
Graphical Abstract

The contents of this page will be used as part of the graphical abstract of HTML only. It will not be published as part of main article.

Tumour recurrence following oesophagectomy for oesophageal cancer is common despite neoadjuvant treatment. We aimed to describe patterns of recurrence and assess risk factors associated with locoregional (LR) and systemic recurrence (SR).